after craniofacial surgery. It has been suggested that an overexpression of transforming growth factor-b2 (Tgf-b2) may be related to craniosynostosis and contribute to postoperative resynostosis. Interference with Tgf-b2 function using neutralizing antibodies may inhibit resynostosis and improve postoperative craniofacial growth; the present study was designed to test this hypothesis. Twenty-nine New Zealand white rabbits with bilateral coronal suture synostosis were used: 1) suturectomy controls (n = 9); 2) suturectomy with nonspecific, control IgG antibody (n = 9); and 3) suturectomy with anti-Tgf-b2 antibody (n = 11). At 10 days of age, a 3 mm Â 15-mm coronal suturectomy was performed. The sites in groups 2 and 3 were immediately filled with 0.1 cc of a slow resorbing collagen gel mixed with either IgG (100 mg/suture) or anti-Tgf-b2 (100 mg/suture). Three-dimensional computed tomography scan reconstructions of the skulls and cephalographs were obtained at 10, 25, 42, and 84 days of age. Computed tomography scan data revealed patent suturectomy sites and significantly (P G 0.05) greater intracranial volumes by 84 days of age in rabbits treated with anti-Tgf-b2 compared with controls. Cephalometric analysis revealed significant (P G 0.05) differences in craniofacial, cranial vault, and cranial base growth by 84 days of age in rabbits treated with anti-Tgf-b2 compared with controls. These data support the initial hypothesis that interference with Tgf-b2 function inhibited postoperative resynostosis and improved cranial vault growth in this rabbit model. Thus, this biologically based therapy may be a potential surgical adjunct in the treatment of infants with craniosynostosis.
Key Words: Craniosynostosis, rabbits, Tgf-b2, neutralizing antibodies, intracranial volume, craniofacial growth C raniosynostosis is a pathologic condition defined as the premature fusion of the sutures of the skull, which is premature relative to the cessation of brain growth. In humans, 95% of brain growth is completed by 6 years of age. 1 The birth prevalence of craniosynostosis is estimated at 300 to 500 per 1,000,000 live births. 2 Premature suture fusion is associated with secondary deformities in the cranial vault, midface, and cranial base. 2Y6 Such skeletal deformities often result in significantly elevated intracranial pressure, 7Y15 altered intracranial volume, 11, 13, 16, 17 and dilation of the subarachnoid spaces. 18, 19 These deformities may result in optic nerve compression, papilledema, and, if left uncorrected, optic atrophy, blindness, 20 cognitive disabilities, and mental retardation.
7,11,21Y24 These severe craniofacial, ocular, and neural abnormalities can lead to extensive, costly, and often recurrent clinical and surgical management problems.
23,25Y33
Current therapy and surgical management for craniosynostosis aim for adequate intracranial volume to allow for normal brain growth and development, a reestablishment of normal intracranial fluid pressure dynamics, and addresses the progressive cosmetic skeletal deformity. 23 ,25Y33 The timing and sequence of these procedures will vary according to the number of affected sutures involved, the severity of the secondary deformities, and the functional and neuropsychologic development of the patient. Although many surgical therapies have been successful in achieving these goals, the suturectomy site frequently resynostoses, 31,34Y40 especially in cases managed with simple suturectomies or linear craniectomies. 34, 40 Pancraniosynostosis has even been reported after surgical correction for single suture synostosis. 41 This rapid resynostosis can increase intracranial pressure and further restrict the growing brain and cranial base. 10, 15, 42 These major complications can require additional surgical procedures with reoperation rates ranging from 6% to 27% of patients. Such multiple procedures increase patient morbidity and mortality. 23,29,31Y33,39,43Y45 The pathogenesis of simple, nonsyndromic craniosynostosis appears to be multifactorial and is not been fully elucidated, 46Y50 although rapid advances have been made in the identification of a number of genetic mutations responsible for craniosynostosis. 46Y48,50,51 Recent research has shown that normal suture maintenance and eventual fusion require soluble, heparin-binding growth factors secreted by the dura mater. 34,49,50,52Y57 The transforming growth factor-b (Tgf-b) isoforms (Tgf-b1, Tgf-b2, and Tgf-b3) are a group of local growth factors that control osteogenic processes in cranial sutures. 34, 49, 50 ,52Y56,58Y68 It has been shown that an abnormal expression patterns of these growth factors (particularly an overexpression of Tgf-b2) was found in craniosynostotic infants 60, 61 and rabbits 50, 64, 65 and are thought to contribute to premature suture fusion. 34,49,50,53,59,60,62Y65,68,69 Recently, mutations in Tgf-b receptors (Tbr-I and Tbr-II) have also been identified to play a causal role in craniosynostosis. 58, 68 It was also demonstrated that inhibition of Tgf-b2 using neutralizing antibodies rescued normally fusing rodent sutures from obliteration. 59, 61, 67 Recent advances in understanding the relationship between the dura mater and the overlying bone and the molecular events occurring during normal suture fusion and craniosynostosis, 34, 50, 56, 70 Recent studies from our laboratory have shown that interfering with Tgf-b2 function using neutralizing antibodies inhibited postoperative resynostosis in craniosynostotic rabbits. 50, 75 However, it is still unclear whether cranial vault and craniofacial growth were improved after this procedure. The present study examines serial growth data in these rabbits 50, 75 to test the hypothesis that inhibition of Tgf-b2 function through the use of neutralizing antibodies will inhibit postoperative resynostosis after suturectomy, thus improving subsequent craniofacial growth in a rabbit model of human, nonsyndromic craniosynostosis.
MATERIALS AND METHODS

Sample
T wenty-nine 10-day-old New Zealand white rabbits (Oryctolagus cuniculus) with bilateral coronal suture synostosis were used in the present study. All rabbits were born in our ongoing breeding colony of congenitally synostosed rabbits at the University of Pittsburgh, Department of Anthropology vivarium. Morphologically, the synostosed rabbits from this colony are very similar to human infants with congenital bicoronal craniosynostosis.
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Phenotypically, these rabbits show bony bridging at the coronal sutures as early as 21 days' gestation, obliterated coronal sutures at birth, coronal ridging and brachycephalic cranial vaults by 10 days of age, and secondary changes in the cranial base, brain, and intracranial volume by 42 days of age. 5, 9, 76 The rabbits were randomly assigned to three groups as follows: group 1, suturectomy with no treatment, which served as the surgical control group (n = 9); group 2, suturectomy with nonspecific, control IgG antibody in a slow release collagen vehicle, which served as the antibody control group (n = 9); and group 3, suturectomy with anti-Tgf-b2 antibody in a slow release collagen vehicle, which served as the treatment group (n = 11). This study was reviewed and approved by the University of Pittsburgh, Institutional Animal Care and Use Committee.
Surgery
At 10 days of age, all rabbits were anesthetized with an intramuscular injection (0.59 mL/kg) of a solution of 91% Ketaset (ketamine hydrochloride, 100 mg/mL; Aveco Co., Inc., Fort Dodge, IA) and 9% Rompun (xylazine, 20 mg/mL; Mobay Corp., Shawnee, KS). The scalps were then shaved, depilated, and prepared for surgery. The calvaria were exposed using a midline scalp incision and the skin reflected laterally to the supraorbital borders. Holes were then made in the periosteum and bone using a fine dental bur (0.5 mm) and packed with silver dental amalgam to serve as radiopaque markers. The holes were placed in quadrants, 2 mm anterior and posterior to the coronal sutures and 2 mm lateral to the sagittal and interfrontal sutures. After marker implantation, a 3-mm-long by 15-mmwide strip of frontal and parietal bones, including the entire length and width of the synostosed coronal suture, was osteotomized using a surgical burr and removed in one piece from pterion to pterion ( Fig 1A) . Care was taken to preserve the meningeal (fibrous) layer of the dura, the regional vascularity, and the amalgam markers in the frontal and parietal bones. All of the animals received postoperative intramuscular injections (2.5 mg/kg) of Baytril (Bayer Corp., Shawnee Mission, KS) as a prophylaxis for infection.
The rabbits in the suturectomy control group received only the suturectomy procedure. The periosteal and skin incisions were then closed with 4-0 resorbable Vicryl suture (Ethicon, Somerville, NJ). In the rabbits in the other two groups, the suturectomy sites were immediately filled with 0.1 cc of a slow-resorbing collagen gel mixed with either IgG antibody (100 mg/suture) or a Tgf-b2 neutralizing antibody (100 mg/suture) ( Fig 1B) . The collagen vehicle was a highly purified, slow-resorbing (963 days in rabbit perisutural tissues 50, 56 ) bovine collagen type I gel and was provided by NeuColl, Inc. (Campbell, CA). The gel is U.S. Food and Drug Administration-approved for human subdermal application and supplied at a density of 65 mg/mL, which is much higher than other collagen gels. 50, 59 The gel is diluted to 1:1 with the antibody solution. The IgG and anti-Tgf-b2 antibodies (human TGF-b2 affinity purified polyclonal antibodies) were commercially available (catalog no. AF-302-NA; R and D Systems, Minneapolis, MN). The antibodies were mixed, under sterile conditions, with 100-mL aliquots of the collagen gel to a final concentration of 100 mg per gel aliquot in a 1-mL syringe. The final concentration of the antibody in the collagen gel was 1 mg/ 1 mL (32 mg/mL collagen) with 100 mL/suture. This 
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volume assured that the entire suturectomy site was filled with vehicle and antibody (Fig 1B) . After gel injection, the periosteum and skin incisions were closed with 4-0 resorbable Vicryl suture (Ethicon). Optimal anti-Tgf-b2 antibody dosage and biodegradation kinetics of the collagen vehicle were determined in vitro and has been reported by one of the coauthors (AMM). 50, 59, 77 
Data Collection
Somatic and skull growth data from threedimensional computed tomographic (3-D CT) scans and cephalographs were obtained from all rabbits at 10, 25, 42, and 84 days of age. At 84 days of age, approximately 80% to 90% of total calvarial and brain growth is completed in the rabbit. 5, 76, 78 Computed Tomography Serial 3-D CT scans were taken with the rabbits sedated with an intramuscular injection (0.40 mL/kg) of a solution of 91% Ketaset (ketamine hydrochloride, 100 mg/mL, Aveco Co., Inc.) and 9% Rompun (xylazine, 20 mg/mL; Mobay Corp.). The computed tomography scans of the rabbits were taken in the sagittal plane using a GE HiSpeed Advantage Scanner (dual field of view = 24.0Y18.0 cm; mA = 120Y150; kV = 120; Fairfield, CT) at a thickness of 1 mm. The endocortical boundaries of the cranial cavities were automatically and manually traced, reconstructed, and the indirect intracranial volumes were calculated using Allegro Software (ISG Technologies, Atlanta, GA) on a Sun Workstation (Santa Clara, CA) 16, 17 All of the measurements were taken blind as to rabbit group identity and intraobserver, repeated measurement reliability was calculated (r = 0.941; P G 0.01) on a randomly drawn sample (20%) of rabbits.
Cephalometry
Serial lateral and dorsoventral head radiographs (including the front right paw) were taken with the rabbits sedated with an intramuscular injection (0.40 mL/kg) of a solution of 91% Ketaset (ketamine hydrochloride, 100 mg/mL, Aveco Co., Inc.) and 9% Rompun (xylazine, 20 mg/mL; Mobay Corp.). The heads were immobilized in a specifically designed cephalostat and a Phillips Oralix 70 (Washington, DC) dental x-ray unit was used at an exposure of 50 kV, 7 mA and a .17-to .50-second exposure time, and a tube-to-cassette distance was held constant at 152 cm. 5, 64, 79 The cephalographs were viewed on a light box and a number of cephalometric landmarks and amalgam markers on either side of the coronal suturectomy site were identified and traced on acetate tracing paper. The tracings were then scanned using a Hewlett-Packard ScanJet 5370 C scanner (Palo Alto, CA) and the digital images were stored on a Gateway2000 PC (Irvine, CA). The landmarks were assigned Cartesian (x and y) coordinates and the distances between the markers were measured using the Dolphin image analysis software program (Dolphin Imaging & Management Solutions, Sacramento, CA). The landmarks and markers that were identified from the cephalographs included: 1) CS, anterior and posterior coronal suture markers; 2) ALS, anterior lambdoidal suture; 3) MOP, maximum occipital point; 4) OP, opisthion; 5) SOS, sphenooccipital synchondrosis; 6) FE, frontoethmoidal point; 7) UMP, upper molar point; 8) PR, prosthion; 9) PSES, presphenoethmoidal synchondrosis; and 10) the proximal and distal articular surfaces of the third, right metacarpals viewed on the dorsoventral cephalographs. Somatic, sutural, and craniofacial growth were assessed by calculating age-related changes in a number of measures, including third metacarpal length; amalgam marker separation at the coronal suturectomy site (CS); overall craniofacial length (MOP-PR); cranial base length (SOS-PSES); and the cranial vault shape (height/length) index ([ALS-SOS/OP-FE]*100).
All of the measurements were performed blind with regard to group identity. A random sample of 10% of the radiographs were traced and measured twice. Intraobserver, repeated measurement 
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reliability was calculated at r = 0.963 (P G 0.01) with a 3.15% standard error of measurement.
Statistical Analysis
The mean and standard deviation for the metatarsal length, marker separation difference, various cranial distances, indices, and intracranial volumes were calculated at each age and compared among groups using a 3 Â 1 (group by single age) one-way analysis of variance. Significant intergroup differences were assessed using the least significant differences multiple comparison test. All of the data were analyzed using SPSS 12.0 for windows (SPSS, Inc., Chicago, IL) and the differences were considered significant if P G 0.05.
RESULTS
Somatic Growth
T he mean third metacarpal length in all three groups of rabbits increased similarly from approximately 6 mm at 10 days of age to 18 mm at 84 days of age (Fig 2) . No significant differences were noted among any groups at 10 (F = 0.31; not 
Suturectomy Site Patency and Intracranial Volume
Serial 3-D CT reconstructions (Fig 3) showed very rapid reossification of the coronal suturectomy site in the suturectomy control, and to a lesser extent, in the IgG control group, compared with the anti-Tgf-b2 group by 42 days of age (32 days postoperation). The sites demonstrated extensive new bone formation at the margins of the suturectomy, which eventually resynostosed in the control groups by 84 days of age (74 days postoperation) (Fig 3) . In contrast, rabbits that received postoperative anti-Tgf-b2 antibody therapy showed some resynostosis and bony bridging of the suturectomy site by 84 days of age; however, most rabbits still had sizeable and patent defect sites at this time.
The 3-D CT scan reconstructions also showed gross differences in the intracranial contents by 42 days of age (Figs 3 and 4) . The reconstructions were longer in the anteroposterior dimension, narrower transversely, and less superiorly displaced in the anti-Tgf-b2 antibody group compared with both the suturectomy and IgG control groups. 
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The mean intracranial volume in all of the groups increased after suturectomy and ranged from an average of 3.75 cm 3 at 10 days of age to an average of 6.2 cm 3 at 84 days of age in the suturectomy and IgG control groups (Fig 5) . Rabbits in the anti-Tgf-b2 group demonstrated similar intracranial volumes at 10 and 25 days and then greater volumes at 42 and 84 days of age, which averaged 6.8 cm 3 . One-way analysis of variance by age revealed no significant group differences at 10 (F = 0.27; NS), 25 (F = 0.70; NS), and 42 (F = 0.34; NS) days of age. A significant group difference was noted at 84 days of age (F = 2.96; P G 0.05). Intracranial volume was significantly greater in the anti-Tgf-b2 group compared with the other two control groups (Fig 5) .
Cephalometry
Qualitative analysis of the serial cephalographs revealed that the rabbits in the anti-Tgf-b2 therapy had more patent and radiolucent suturectomy sites, flatter cranial vaults, and longer craniofacial skeletons that the other two groups by 84 days of age (Figs 3 and 6) .
Quantitative analysis of the serial cephalographs revealed that both the mean coronal suture marker separation and mean overall craniofacial length increased in the anti-Tgf-b2 therapy group by 25 days of age and remained greater than in both controls groups through 84 days of age (Fig 7) . No significant group differences in coronal suture marker separation was noted at 25 (F = 0.95; NS) days of age, whereas a significant group difference 
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was noted at 42 (F = 3.95; P G 0.05) and 84 days of age (F = 3.11; P G 0.05). Similar findings were found for the overall craniofacial length analysis. No significant group differences were noted at 10 (F = 1.71; NS), 25 (F = 0.44; NS), and 42 (F = 2.26; NS) days of age, whereas a significant group difference was noted at 84 days of age (F = 3.36; P G 0.05).
Cephalometric analysis of the cranial base and the cranial vault shape also revealed similar findings to the suturectomy site and skull growth data. The mean cranial base length increased in the anti-Tgf-b2 therapy group by 25 days of age and remained greater than in both controls groups through 84 days of age (Fig 8) . No significant group differences were noted at 10 (F = 0.55; NS), 25 (F = 1.50; NS), and 42 (F = 1.18; NS) days of age, whereas a significant group difference was noted at 84 days of age (F = 3.28; P G 0.05). Mean cranial vault shape index (cranial vault height/cranial vault length) decreased in the anti-Tgf-b2 therapy group by 25 days of age and remained lower than in both controls groups through 84 days of age (Fig 8) . No significant group differences were noted at 10 (F = 0.89; NS), 25 (F = 1.46; NS), and 42 (F = 1.25; NS) days of age, whereas a significant group difference was noted at 84 days of age (F = 2.89; P G 0.05).
DISCUSSION T
he results from the present study demonstrate that a course of treatment with Tgf-b2-neutralizing antibodies in a slow-release collagen vehicle after surgical release of a prematurely fused coronal suture resulted in significantly improved intracranial volume and craniofacial growth. These findings were probably a result of inhibition of postoperative reossification of the suturectomy site 50, 75 and are consistent with in vitro studies that show inhibition of normal rodent suture fusion by interfering with Tgf-b2 function. 34, 50, 56, 59, 67 The Tgf-bs are potent growth regulatory molecules that influence craniofacial development in early embryonic stages and in subsequent stages of cell differentiation. The activated isoforms are particularly important in suture biology because they mediate proliferation and differentiation of osteoblastic suture cells and affect fusion in vitro and in vivo.
34,49,50,52Y56,58Y60,62Y67,80 Although it is still unclear how the different Tgf-b isoforms function to regulate suture patency and fusion, it has been shown that each isoform binds and signals through the same set of receptors. 49, 50, 52, 56 Blocking Tgf-b2 binding activity and function using neutralizing antibodies may allow Tgf-b3 to bind to its receptor without competition, thus reducing the antagonistic effects of these two isoforms in regulating postoperative resynostosis. 34,50,56,63,66Y68 Tgf-bs may also regulate postoperative resynostosis in much the same way that they regulate suture fusion, by controlling the number of cells in the suture and surrounding bone fronts by regulating cell proliferation and apoptosis. 50, 56, 67 Postoperative resynostosis in rabbits from this colony may be a result of increased cell proliferation rates from Tgf-b2 overexpression as evidenced by the significantly increased number of osteoblasts and osteocytes and new bone area seen in the suturectomy margins in control rabbits compared with anti-Tgf-b2 antibody treated rabbits in this study. 50, 75 These findings are consistent with data from other studies showing calvarial bone dysgenesis and sutural agenesis in transgenic Tbr mutant and Tgf-b2 knockout mice. 58, 81 There is also a complex interplay among all three of the Tgf-b isoforms, their receptors, other growth factors (e.g., fibroblast growth factors, bonemorphogenic proteins), and various developmental genes (e.g., MSX2, TWIST, RUNX2), which may also be involved in both regulating suture patency and postoperative resynostosis. 34,48Y51,56,63,65,70,82 The objectives of surgical management of craniosynostosis are to provide adequate intracranial volume to allow for normal brain growth and development, 7,11,16Y19,21Y24,83 to reestablish normal intracranial fluid pressure dynamics 7Y15 and to correct the progressive appearance related deformity. 2,4Y6,70 Although these surgical procedures are successful in meeting their objectives, the craniectomy sites frequently reossify (in 30% to 100% of reported cases), 31,34Y40 and this may occur very rapidly (in some cases as early as 6 months postoperatively), especially in sporadic or isolated cases in which simple suturectomies or linear craniectomies are used. 34, 35, 40 Fusion of all the cranial vault sutures (pancraniosynostosis), even those previously unaffected, has even been reported after surgical correction for single suture synostosis. 41 This rapid resynostosis can increase intracranial pressure, further restricting the growing brain and cranial base, and alter craniofacial growth. 10, 15, 17, 26, 42, 50 Fig 7 Mean (T standard error) coronal suture marker separation and craniofacial length by group and age. Note the significantly increased marker separation at 42 and 84 days and craniofacial length at 84 days of age in the antitransforming growth factor-b2 antibody-treated group compared with the suturectomy and IgG control groups (asterisks denotes significant differences).
Fig 8
Mean (T standard error) cranial base length and cranial vault shape index by group and age. Note the significantly increased cranial base length and different shape index at 84 days of age in the anti-transforming growth factor-b2 antibody-treated group compared with the suturectomy and IgG control groups (asterisk denotes significant differences).
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Historically, a number of different strategies have been used to prevent postoperative reossification. 23, 32, 43, 84, 85 Initial therapies involved wrapping the intact bony margins with a mechanical barrier attempting to prevent previously released stenosed sutures from closing again. However, new bone rapidly overgrew the barrier and reossified the suturectomy site, and new suture formation was never observed. 43 Other therapies were designed to chemically damage the dura and reduce its osteogenic potential. 43, 86, 87 Suturectomy site patency increased with the use of these techniques, but seizures and neurologic problems occurred, probably as a result of the toxicity of the chemical adjuvants. 23, 43 Auto-or allotransplantation of normal sutures into the suturectomy site have also been used to replace missing growth sites, but rapid resynostosis of the transplanted suture was also seen in both human infants 40 and rabbits with familial craniosynostosis. 42 Another approach involves the radical surgical repositioning of the calvarial bones, performed in part to keep the margins of the craniectomy sites from physically reapproximating and resynostosing. 23,25Y34,43,84 Although sutural reossification is less of a problem with these extensive techniques, the rates for other complications from these high-risk procedures range from approximately 15% to 25% and include osseous relapse and instability, severe intraoperative blood loss, seizures, infections, soft tissue necrosis, eye injuries, and death. 23,28,31,33,39,43Y45 The major complications can require additional surgical procedures to correct (reoperation rates range from 6% to 27%) 44, 45 and are more frequent in infants with syndromic craniosynostosis.
14 Concomitantly, this increases patient morbidity and mortality.
Although improvements in the intracranial volume and craniofacial growth in this rabbit model of craniosynostosis after anti-Tgf-b2 therapy are promising, there are also a number of practical problems related to the human use of these biologically based therapies. 50, 75 Brain growth in humans is approximately 95% complete by 6 years of age 1 compared with 84 days in rabbits. Thus, sutures or surgical sites should theoretically remain patent for at least this long to allow unrestricted brain and neurocapsular growth and development in human infants. Although there is controversy regarding the timing of primary surgical release (which ranges from 3Y12 months of age), and reossification in some cases has been seen by 6 months postoperatively, these biologically based therapies would require sustained growth factor release for approximately 5 years to inhibit resynostosis and provide a clinically relevant therapeutic effect. However, in human infants, approximately 60% of brain growth is finished by the first year of life and 90% is finished by the second year.
1 Therefore, an interference with resynostosis may be potentially more efficacious in the immediate postoperative period during the first year and less so in the second year and beyond. Given the present technology for the delivery of growth factors, antibodies, and genes, 50,71Y 74,77 multiple dosing would likely have to be performed to deliver the requisite amounts. Vehicles would also have to be designed to achieve the prolonged delivery required for a biologically based therapy to be effective.
These results support our initial hypothesis that an interference with Tgf-b2 function would inhibit postoperative resynostosis and improve cranial vault growth in this rabbit model. These findings also suggest that this biologically based therapy may be a potential adjunct to the surgical treatment of infants with craniosynostosis, particularly once the technologic aspects of delivery systems and gene therapy are improved.
